Related Experiment Video
Updated: Jun 3, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Integrated profiling of diffuse large B-cell lymphoma with 7q gain
Ekaterina Chigrinova1, Michael Mian, Yulei Shen
1Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland, via Vincenzo Vela 6, Bellinzona, Switzerland.
British Journal of Haematology
|March 23, 2011
Summary
Chromosome 7 gains in diffuse large B-cell lymphoma (DLBCL) are linked to better outcomes with R-CHOP treatment. These genetic changes correlate with specific patient demographics and disease characteristics.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
- Understanding genetic alterations is crucial for improving DLBCL treatment strategies.
Purpose of the Study:
- To characterize diffuse large B-cell lymphoma (DLBCL) with chromosome 7 gains (7q+).
- To correlate these genetic gains with clinical features, treatment response, and molecular profiles.
Main Methods:
- Combined clinical data with genomic, RNA, and microRNA (miRNA) profiling.
- Utilized real-time polymerase chain reaction (PCR) for miRNA validation.
Main Results:
- Chromosome 7 gains were associated with older age (>60 years) and female gender.
- 7q+ DLBCL showed a trend towards higher complete response rates, lower mortality, and improved overall survival with R-CHOP therapy.
- These genetic lesions were inversely correlated with bone marrow involvement and extranodal disease sites.
- Differentially expressed genes and miRNA targets were identified, with MIR96, MIR182, MIR589, and MIR25 significantly upregulated in 7q+ DLBCL.
Conclusions:
- Chromosome 7 gains represent a distinct molecular subtype of DLBCL.
- 7q+ DLBCL may predict a favorable prognosis and better response to R-CHOP treatment.
- Further research into the functional role of upregulated miRNAs in 7q+ DLBCL is warranted.
